OBI-992, a novel TROP2 targeting antibody-drug conjugate, displayed excellent antitumor efficacy in various animal models

被引：0
|
作者：
Li, Wan-Fen
Chiang, Ming-Feng
Weng, Hao-Cheng
Yang, Jhih-Jie
Wu, Hsin-Shan
Lin, Chun-Jung
Chiu, Ping-Tzu
Lai, Ming-Tain
机构：
来源：
CANCER RESEARCH | 2024年 / 84卷 / 06期
关键词：
D O I：
10.1158/1538-7445.AM2024-1893
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1893
引用
收藏
页数：2
相关论文
共 50 条
  • [1] OBI-992, a Novel TROP2-Targeted Antibody-Drug Conjugate, Demonstrates Antitumor Activity in Multiple Cancer Models
    Li, Wan-Fen
    Chiang, Ming-Feng
    Weng, Hao-Cheng
    Yang, Jhih-Jie
    Wu, Hsin-Shan
    Wu, Szu-Yu
    Chen, Yu-Jung
    Lu, Chi-Huan
    Tu, Jyy-Shiuan
    Hsu, Ren-Yu
    Shia, Chi-Sheng
    Huang, Teng-Yi
    Lai, Ming-Tain
    MOLECULAR CANCER THERAPEUTICS, 2025, 24 (02) : 163 - 175
  • [2] OBI-992, a novel TROP2 targeting antibody drug conjugate demonstrates superior in vivo PK/PD properties and a favorable safety profile
    Shia, Chi-Sheng
    Wen, Shih-Ni
    Hsu, Ren-Yu
    Tu, Jyy-Shiuan
    Chang, Hui-Wen
    Li, Wan-Fen
    Lai, Ming-Tain
    CANCER RESEARCH, 2024, 84 (06)
  • [3] In vitro characterization of a novel TROP2-targeting antibody-drug conjugate OBI992
    Kuo, Tzer-Min
    Chang, Ting-Yu
    Huang, Jye-Yu
    Tang, Wei-Chien
    Lin, Chun-Jung
    Wu, Yi-Chen
    Lu, Chi-Huan
    Weng, Hao-Cheng
    Chen, Yu-Jung
    Tsao, Yu-Hsuan
    Wei, Cheng-Yen
    Shen, Lifen
    Li, Wan-Fen
    Lai, Ming-Tain
    CANCER RESEARCH, 2024, 84 (06)
  • [4] Preclinical evaluation of a novel antibody–drug conjugate OBI-992 for Cancer therapy
    Ting-Yu Chang
    Chun-Jung Lin
    Shih-Ni Wen
    Yi-Chen Wu
    Cheng-Yen Wei
    Jye-Yu Huang
    Yu-Hsuan Tsao
    Yu-Jung Chen
    Wei-Chien Tang
    Yuen-Chin Wu
    Wei-Han Lee
    Teng-Yi Huang
    Tzer-Min Kuo
    Wan-Fen Li
    Ming-Tain Lai
    Scientific Reports, 15 (1)
  • [5] YH012, a novel bispecific anti-HER2 and TROP2 antibody-drug conjugate, exhibits potent antitumor efficacy
    Shang, Chengzhang
    Yang, Liu
    Zhang, Jiyong
    Han, Yanfei
    Li, Zhuolin
    Han, Zhenyan
    Li, Jun
    Meng, Ying
    An, Gao
    Yang, Hao
    An, Wenqian
    Chen, Lei
    Charpentier, John
    CANCER RESEARCH, 2022, 82 (12)
  • [6] Preclinical activity of datopotamab deruxtecan, a novel TROP2 directed antibody-drug conjugate targeting trophoblast cell-surface antigen 2 (TROP2) in ovarian carcinoma
    McNamara, Blair
    Greenman, Michelle
    Bellone, Stefania
    Santin, Luca A.
    Demirkiran, Cem
    Mutlu, Levent
    Hartwich, Tobias Max Philipp
    Yang-Hartwich, Yang
    Ratner, Elena
    Schwartz, Peter E.
    Santin, Alessandro D.
    GYNECOLOGIC ONCOLOGY, 2024, 189 : 16 - 23
  • [7] Trop2 deal heats up antibody-drug conjugate space in cancer
    Shaffer, Catherine
    NATURE BIOTECHNOLOGY, 2021, 39 (02) : 128 - 130
  • [8] A new TROP2-targeting antibody-drug conjugate shows potent antitumor efficacy in breast and lung cancers
    Zhou, Dan-dan
    Zhai, Xiao-tian
    Zhang, Lan-wen
    Xie, Zi-hui
    Wang, Ying
    Zhen, Yong-su
    Gao, Rui-juan
    Miao, Qing-fang
    NPJ PRECISION ONCOLOGY, 2024, 8 (01)
  • [9] hIMB1636-MMAE, a Novel TROP2-Targeting Antibody-Drug Conjugate Exerting Potent Antitumor Efficacy in Pancreatic Cancer
    Sun, Li-ping
    Bai, Wei-qi
    Zhou, Dan-dan
    Wu, Xiao-fan
    Zhang, Lan-wen
    Cui, A-long
    Xie, Zi-hui
    Gao, Rui-juan
    Zhen, Yong-su
    Li, Zhuo-Rong
    Miao, Qing-fang
    JOURNAL OF MEDICINAL CHEMISTRY, 2023, 66 (21) : 14700 - 14715
  • [10] Antitumor Activity and Biomarker Analysis for TROP2 Antibody-Drug Conjugate Datopotamab Deruxtecan in Patient-Derived Breast Cancer Xenograft Models
    Meric-Bernstam, Funda
    Yuca, Erkan
    Evans, Kurt W.
    Zhao, Ming
    Maejima, Takanori
    Karibe, Tsuyoshi
    Raso, Maria Gabriela
    Tang, Ximing
    Zheng, Xiaofeng
    Rizvi, Yasmeen Qamar
    Akcakanat, Argun
    Scott, Stephen M.
    Wang, Bailiang
    Byers, Lauren A.
    Tripathy, Debu
    Okajima, Daisuke
    Damodaran, Senthil
    CLINICAL CANCER RESEARCH, 2025, 31 (03) : 573 - 587
12345